FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Richards Christos						2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [CHRS]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
					01	3. Date of Earliest Transaction (Month/Day/Year) 01/10/2020									Officer below)	(give title		Other (s below)	pecify
(Street) REDWO CITY (City)	C.		94065 (Zip)		- 4. I -	f Ame	f Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Ch Line) X Form filed by One Reporting Form filed by More than One Person										rting Persor	.	
		Tab	le I - Non	-Deriv	vativ	e Se	curities	s Ac	quired, D)isp	osed o	f, or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ear) i	2A. Deemed Execution Date, f any (Month/Day/Year		Transaction Dispo			ities Acquired (A) od Of (D) (Instr. 3, 4		and Securitie Beneficia Owned F Reported		es Formally (D) of (I) (II)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Table II - Derivati					ativo.	Sooi	ıritioo	Λοαι		v 	Amount	(D) P1			(Instr. 3 a	and 4)			
									, options						wneu				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day)	Date,	4. Transactic Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		S	s. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amour or Number of Shares	er					
Stock Option (Right to	\$17.73	01/10/2020			A		20,000		(1)	0	1/10/2030	Common Stock	20,00	00	\$0.00	20,000)	D	

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ Jean-Frederic Viret, as

Attorney-in-Fact for Christos 01/14/2020

Richards

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.